Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities
| Autor: | Ravindra Ganesh, Caroline G. Wilker, Lori L Arndt, Dennis M. Bierle, Sara N. Hanson, Sidna M. Tulledge-Scheitel, Raymund R. Razonable |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty COVID-19 Vaccines medicine.drug_class breakthrough covid-19 Comorbidity Monoclonal antibody Lower risk Risk Factors Internal medicine medicine Humans Immunology and Allergy Mass index SARS-CoV-2 business.industry Brief Report Vaccination Antibodies Monoclonal COVID-19 Odds ratio Middle Aged Confidence interval AcademicSubjects/MED00290 Infectious Diseases Cohort outcome Number needed to treat Female Median body casirivimab-imdevimab business hospitalization |
| Zdroj: | The Journal of Infectious Diseases |
| ISSN: | 1537-6613 0022-1899 |
| Popis: | Background Breakthrough coronavirus disease 2019 (COVID-19) may occur in fully vaccinated persons. Methods We assessed the clinical outcomes of breakthrough COVID-19 in fully vaccinated individuals. Results In this cohort of 1395 persons (mean age, 54.3 years; 60% female; median body mass index, 30.7) who developed breakthrough COVID- 19, there were 107 (7.7%) who required hospitalization by day 28. Hospitalization was significantly associated with the number of medical comorbidities. Antispike monoclonal antibody treatment was significantly associated with a lower risk of hospitalization (odds ratio, 0.227; 95% confidence interval, 0.128–0.403; P < .001). The number needed to treat (NNT) to prevent 1 hospitalization was 225 among the lowest risk patient group compared with NNT of 4 among those with highest numbers of medical comorbidity. Conclusions Monoclonal antibody treatment is associated with reduced hospitalization in vaccinated high-risk persons with mild to moderate COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|